Immunotec
TINA.org investigated Immunotec as part of its larger investigations into unsubstantiated disease-treatment claims and atypical income claims used by DSA-member companies.
To read more about TINA.org’s DSA Health Claims Investigation, click here.
To read more about TINA.org’s DSA Income Claims Investigation, click here.
Timeline
Timeline
January 6, 2022: The DSSRC issues a case decision finding that Immunotec used unsubstantiated disease-treatment claims to market its products, including that they can help with infertility, autism, cancer, and pneumonia, among other conditions, and atypical earnings claims to market its business opportunity, including the ability to earn immediate and long-term income. According to the DSSRC, the company removed several posts at issue, prompting the DSSRC to close its investigation.
January 15, 2018: Immunotec responds to TINA.org stating that it is taking steps to remove the deceptive income claims identified.
December 18, 2017: As part of its 2017 investigation into all DSA-member companies, TINA.org notifies Immunotec of findings that it uses atypical income claims to market the business opportunity.
December 12, 2016: Immunotec responds to TINA.org stating that it is taking steps to remove the deceptive health claims identified.
November 22, 2016: As part of its 2016 investigation into DSA-member companies that sell nutritional supplements, TINA.org notifies Immunotec of findings that it uses unsubstantiated disease-treatment claims to market its products.